Literature DB >> 11323532

A reversible tracer analysis approach to the study of effective dopamine turnover.

V Sossi1, D J Doudet, J E Holden.   

Abstract

Changes in dopamine turnover resulting from disease states such as Parkinson's disease may be reflected in corresponding changes in the kinetics of the positron emission tomographic tracer [(18)F]fluorodopa. The authors had previously refined the conventional irreversible-tracer graphical approach to determine both the uptake rate constant K(i) and the rate constant kloss that describes the slow loss of the trapped kinetic component. Because these parameters change in the opposite sense with disease, their ratios may be more powerfully discriminating than either one alone. The ratio k(loss)/K(i) is indicative of effective dopamine turnover. Its inverse, K(i)/k(loss), can be interpreted as the effective distribution volume (EDV) of the specific uptake compartment referred to the fluorodopa concentration in plasma. Here the authors present a new approach to the estimation of EDV based on reversible-tracer graphical methods. When implemented with a plasma input function, the method evaluates EDV directly. When implemented with a tissue input function, the outcome is proportional to the ratio of the distribution volumes of the specific uptake and precursor compartments. Comparison of the new and previous approaches strongly validates this alternative approach to the study of effective dopamine turnover.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323532     DOI: 10.1097/00004647-200104000-00015

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  22 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET.

Authors:  I Lopes Alves; Sanne K Meles; Antoon Tm Willemsen; Rudi A Dierckx; Ana M Marques da Silva; Klaus L Leenders; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-19       Impact factor: 6.200

4.  Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis.

Authors:  Teresa M Karrer; Anika K Josef; Rui Mata; Evan D Morris; Gregory R Samanez-Larkin
Journal:  Neurobiol Aging       Date:  2017-05-12       Impact factor: 4.673

Review 5.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

6.  Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Daniel F Drake; Bobbi J Woolwine; James R Spivey; Ronald J Crowe; John R Votaw; Mark M Goodman; Andrew H Miller
Journal:  Arch Gen Psychiatry       Date:  2012-10

7.  Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease.

Authors:  Liane Oehme; Maria Perick; Bettina Beuthien-Baumann; Martin Wolz; Alexander Storch; Matthias Löhle; Birgit Herting; Jens Langner; Jörg van den Hoff; Heinz Reichmann; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

8.  Influence of O-methylated metabolite penetrating the blood-brain barrier to estimation of dopamine synthesis capacity in human L-[β-(11)C]DOPA PET.

Authors:  Keisuke Matsubara; Yoko Ikoma; Maki Okada; Masanobu Ibaraki; Tetsuya Suhara; Toshibumi Kinoshita; Hiroshi Ito
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

Review 9.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

10.  In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Siobhan McCormick; Chenoa Mah; James E Holden; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.